Is Iterum Therapeutics plc (ITRM) Halal?

NASDAQ Healthcare Ireland $2M
✗ NOT HALAL
Confidence: 90/100
Iterum Therapeutics plc (ITRM) is Not Halal under AAOIFI Standard 21. The company's debt ratio of 516.3% exceeds the 30% threshold, indicating excessive interest-bearing debt relative to market capitalization. Iterum Therapeutics plc operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 516.3%
/ 30%
273.5%
/ 30%
0.7%
/ 30%
N/A ✗ NOT HALAL
DJIM 516.3%
/ 33%
273.5%
/ 33%
0.7%
/ 33%
N/A ✗ NOT HALAL
MSCI 102.1%
/ 33%
54.1%
/ 33%
0.1%
/ 33%
N/A ✗ NOT HALAL
S&P 516.3%
/ 33%
273.5%
/ 33%
0.7%
/ 33%
N/A ✗ NOT HALAL
FTSE 102.1%
/ 33%
54.1%
/ 33%
0.1%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-0.72
P/B Ratio
-0.2
EV/EBITDA
-1.3
EV: $25M
Revenue
$0
Beta
3.0
High volatility
Current Ratio
2.1

Profitability

Gross Margin 29.7%
Operating Margin -1982.3%
Net Margin 0.0%
Return on Assets (ROA) -53.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$27M
Free Cash Flow-$27M
Total Debt$46M
Current Ratio2.1
Total Assets$45M

Price & Trading

Last Close$0.18
50-Day MA$0.24
200-Day MA$0.56
Avg Volume1.1M
Beta3.0
52-Week Range
$0.03
$1.42

About Iterum Therapeutics plc (ITRM)

CEO
Mr. Corey N. Fishman
Employees
9
Sector
Healthcare
Industry
Biotechnology
Country
Ireland
Exchange
NASDAQ
Market Cap
$2M
Currency
USD

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Iterum Therapeutics plc (ITRM) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Iterum Therapeutics plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Iterum Therapeutics plc's debt ratio?

Iterum Therapeutics plc's debt ratio is 516.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 102.1%.

What are Iterum Therapeutics plc's key financial metrics?

Iterum Therapeutics plc has a market capitalization of $2M.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.